Trials / Completed
CompletedNCT02595762
A Study of Treatment Patterns and Outcomes in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Unresectable Locally Advanced or Metastatic Breast Cancer
A Disease Registry Study to Prospectively Observe Treatment Patterns and Outcomes in Patients With HER2-Positive Unresectable Locally Advanced or Metastatic Breast Cancer
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 110 (actual)
- Sponsor
- Hoffmann-La Roche · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This disease registry is a prospective, multicenter non-interventional study designed to observe anti-cancer treatment regimens and clinical outcomes in participants with HER2-positive unresectable locally advanced breast cancer (LABC) or metastatic breast cancer (MBC).
Conditions
Timeline
- Start date
- 2016-10-30
- Primary completion
- 2023-11-30
- Completion
- 2023-11-30
- First posted
- 2015-11-03
- Last updated
- 2024-08-19
Locations
12 sites across 2 countries: Cyprus, Greece
Source: ClinicalTrials.gov record NCT02595762. Inclusion in this directory is not an endorsement.